(Washington) A vaccine using messenger RNA technology, the same as some COVID-19 vaccines, but this time against AIDS, has shown promising first results in animals, researchers said Thursday.
The vaccine was shown to be safe when given to macaques, and the risk of infection from exposure was reduced by 79%. However, it calls for improvements before it can be tested on humans.
Dr Anthony Fauci co-signed the study
“Despite nearly four decades of efforts by the global scientific community, an effective vaccine to prevent HIV remains an elusive goal,” said immunologist Anthony Fauci, co-author of the study and also adviser to the White House on the health crisis.
“This experimental messenger RNA vaccine combines several features that could overcome the failures of other experimental HIV vaccines, and thus represents a promising approach,” added the director of the US National Institute of Allergy and Infectious Diseases (NIAD). .
Scientists from this institute have carried out this work in collaboration with researchers from Moderna, the American company behind one of the most widely used vaccines against COVID-19.
The study was published Thursday in the journal Nature.
The vaccine was first tested on mice and then on rhesus macaques. These received multiple booster doses over a period of one year. Despite high doses of messenger RNA, the product was well tolerated causing moderate side effects, such as temporary loss of appetite.
At the 58e week, all macaques had developed detectable antibody levels.
From the 60e week, the animals were exposed to the virus weekly, via the rectal mucosa. Since primates are not vulnerable to HIV-1, which infects humans, the researchers used a different, but similar virus, simian HIV (SHIV).
After 13 weeks, only two of the seven immunized macaques were uninfected. But while other unvaccinated macaques developed the disease after about three weeks, those who were immune took an average of eight weeks.
“This level of risk reduction could have a significant impact on viral transmission,” said the study.
The vaccine works by delivering genetic instructions to the body, causing the creation of two proteins characteristic of the virus. These are then assembled to form pseudoviral particles (VLPs), mimicking an infection in order to elicit a response from the immune system.
Scientists note, however, that the levels of antibodies elicited were relatively low, and that a vaccine requiring multiple injections would be difficult to implement in humans.
They thus wish to improve the quality and quantity of VLPs generated, before testing the vaccine on humans.